Inhibrx Biosciences Management
Management criteria checks 3/4
Inhibrx Biosciences' CEO is Mark Lappe, appointed in May 2024, has a tenure of 2.08 years. total yearly compensation is $2.89M, comprised of 24% salary and 76% bonuses, including company stock and options. directly owns 6.31% of the company’s shares, worth $82.45M. The average tenure of the management team and the board of directors is 2.1 years and 2.4 years respectively.
Key information
Mark Lappe
Chief executive officer
US$2.9m
Total compensation
| CEO salary percentage | 24.04% |
| CEO tenure | 2.1yrs |
| CEO ownership | 6.3% |
| Management average tenure | 2.1yrs |
| Board average tenure | 2.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$130m |
| Dec 31 2025 | US$3m | US$695k | -US$140m |
| Sep 30 2025 | n/a | n/a | -US$155m |
| Jun 30 2025 | n/a | n/a | -US$164m |
| Mar 31 2025 | n/a | n/a | US$2b |
| Dec 31 2024 | US$5m | US$695k | US$2b |
Compensation vs Market: Mark's total compensation ($USD2.89M) is below average for companies of similar size in the US market ($USD5.30M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Lappe (59 yo)
Mr. Mark Paul Lappe serves as Chief Executive Officer and Chairperson of the board of directors at Inhibrx Biosciences, Inc. since May 30, 2024 and also served as its President. He co-founded Efficacy Capi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 2.1yrs | US$2.89m | 6.31% $ 82.5m | |
| President | 1.2yrs | US$1.44m | no data | |
| Executive VP | 2.1yrs | US$923.70k | 0% $ 0 | |
| Vice President of Operations | 2.4yrs | no data | no data | |
| Vice President of Accounting | less than a year | no data | no data | |
| Executive VP & Chief Technical Operations Officer | 2.4yrs | no data | no data | |
| EVP & Chief Scientific Officer | 1.2yrs | no data | no data | |
| VP, General Counsel & Corporate Secretary | 2.4yrs | no data | no data | |
| Executive VP & Chief Clinical Development Officer | 2.4yrs | no data | no data |
Experienced Management: INBX's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 2.1yrs | US$2.89m | 6.31% $ 82.5m | |
| Independent Director | 2.1yrs | US$202.69k | 1.53% $ 20.0m | |
| Independent Director | 2.1yrs | US$183.69k | 0.068% $ 891.0k | |
| Independent Director | 2.1yrs | US$192.19k | 7.22% $ 94.4m | |
| Member of INBRX-101 Scientific Advisory Board | 2.4yrs | no data | no data | |
| Member of INBRX-101 Scientific Advisory Board | 2.4yrs | no data | no data | |
| Independent Director | 2.1yrs | US$186.19k | 0.14% $ 1.8m | |
| Member of INBRX-101 Scientific Advisory Board | 2.4yrs | no data | no data | |
| Member of INBRX-101 Scientific Advisory Board | 2.4yrs | no data | no data | |
| Member of INBRX-101 Scientific Advisory Board | 2.4yrs | no data | no data | |
| Member of INBRX-101 Scientific Advisory Board | 2.4yrs | no data | no data |
Experienced Board: INBX's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 05:56 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inhibrx Biosciences, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Reni Benjamin | Citizens JMP Securities, LLC |
| Michael Yee | Jefferies LLC |
| Dara Ahmadi Azar | Stifel, Equities Research |